Size of the Tumor and Pheochromocytoma of the Adrenal Gland Scaled Score (PASS): Can They Predict Malignancy?

Overview

Journal World J Surg

Publisher Wiley

Specialty General Surgery

Date 2010 Aug 13

PMID 20703467

Citations 41

Authors

Amit Agarwal

Prateek K Mehrotra

Manoj Jain

Sushil K Gupta

Anjali Mishra

Gyan Chand

Gaurav Agarwal

A K Verma

S K Mishra

Uttam Singh

Affiliations

Soon will be listed here.

Abstract

Background: Size can predict malignancy in adrenocortical tumors, but the same extrapolation for pheochromocytomas (PCC) is controversial. The goal of this study was to find a correlation between the tumor size and malignant potential of PCC and determine whether the "Pheochromocytoma of the adrenal gland scaled score" (PASS) proposed by Thompson can be applied to predict malignancy.

Methods: A retrospective analysis of patients with PCC operated on from 1991 to 2007 revealed 98 PCC removed from 93 patients. Tumor size was available for 90 tumors. Six (6.4%) patients had proven malignancy. Five familial cases were excluded from the PASS analysis.

Results: Of the benign cases, none developed recurrence or metastasis. There were 54 (60%) tumors > 6 cm and 36 (40%) tumors ≤ 6 cm. All 12 PASS parameters were individually present in higher frequency in the >6-cm group; but the difference was not statistically significant except cellular monotony (p = 0.02). Overall, a PASS ≤ 4 was found in 57 patients. Mean PASS was statistically significantly higher in the >6-cm group (4.4 vs. 3.3, p = 0.04). Of the sporadic benign cases, 21 (41%) patients with tumor size > 6 cm had a PASS of >4, and none of them developed metastasis. PASS ≤ 4 was found in 25 (81%) PCC in the ≤6-cm group, and none developed metastases. PASS ≥ 4 was found in six (19%) patients in the ≤6-cm group, and none developed metastases. 68 patients completed 5-year follow-up, and the remaining had a mean follow-up of 28.7 months. No correlation was found between tumor size and PASS > 4 and PASS ≤ 4 (7.8 cm vs. 7.1 cm; p = 0.23).

Conclusions: Presently there is not enough evidence to indict a large (>6 cm) PCC as malignant. Furthermore, PASS cannot be reliably applied to PCC for predicting malignancy.

Citing Articles

Usefulness of the Primary Tumor Standardized Uptake Value of Iodine-123 Metaiodobenzylguanidine for Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma.

Hirahara M, Nakajo M, Kitazano I, Jinguji M, Tani A, Takumi K Mol Imaging Biol. 2024; 26(6):1005-1015.

PMID: 39294365 PMC: 11635048. DOI: 10.1007/s11307-024-01952-8.

Differences between Patients with Sporadic and Familial Pheochromocytoma-Is It Possible to Avoid Genetic Testing in Certain Patients?.

Munoz M, Febrero B, Abellan M, Hernandez A, Rodriguez J Biomedicines. 2024; 12(6).

PMID: 38927559 PMC: 11202019. DOI: 10.3390/biomedicines12061352.

Identification of Predictors of Metastatic Potential in Paragangliomas to Develop a Prognostic Score (PSPGL).

Iguchi D, Martins Filho S, Soares I, Siqueira S, Alves V, Assato A J Endocr Soc. 2024; 8(7):bvae093.

PMID: 38799767 PMC: 11112433. DOI: 10.1210/jendso/bvae093.

[Metastatic risk factors in pheochromocytoma/paraganglioma].

Rebrova D, Loginova O, Vorobyev S, Vorokhobina N, Kozorezova E, Indeykin F Probl Endokrinol (Mosk). 2024; 70(2):37-45.

PMID: 38796759 PMC: 11145567. DOI: 10.14341/probl13331.

Molecular classification and tumor microenvironment characteristics in pheochromocytomas.

Qin S, Xu Y, Yu S, Han W, Fan S, Ai W Elife. 2024; 12.

PMID: 38407266 PMC: 10942623. DOI: 10.7554/eLife.87586.

References

Wu D, Tischler A, Lloyd R, DeLellis R, de Krijger R, van Nederveen F . Observer variation in the application of the Pheochromocytoma of the Adrenal Gland Scaled Score. Am J Surg Pathol. 2009; 33(4):599-608. DOI: 10.1097/PAS.0b013e318190d12e. View

Harrison L, Gaudin P, Brennan M . Pathologic features of prognostic significance for adrenocortical carcinoma after curative resection. Arch Surg. 1999; 134(2):181-5. DOI: 10.1001/archsurg.134.2.181. View

Van Heerden J, ROLAND C, Carney J, Sheps S, Grant C . Long-term evaluation following resection of apparently benign pheochromocytoma(s)/paraganglioma(s). World J Surg. 1990; 14(3):325-9. DOI: 10.1007/BF01658516. View

Thompson L . Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol. 2002; 26(5):551-66. DOI: 10.1097/00000478-200205000-00002. View

Goldstein R, ONEILL Jr J, Holcomb 3rd G, Morgan 3rd W, Neblett 3rd W, OATES J . Clinical experience over 48 years with pheochromocytoma. Ann Surg. 1999; 229(6):755-64; discussion 764-6. PMC: 1420821. DOI: 10.1097/00000658-199906000-00001. View

John H, ZIEGLER W, Hauri D, Jaeger P . Pheochromocytomas: can malignant potential be predicted?. Urology. 1999; 53(4):679-83. DOI: 10.1016/s0090-4295(98)00612-8. View

Proye C, Vix M, Jansson S, Tisell L, Dralle H, Hiller W . "The" pheochromocytoma: a benign, intra-adrenal, hypertensive, sporadic unilateral tumor. Does it exist?. World J Surg. 1994; 18(4):467-72. DOI: 10.1007/BF00353738. View

Agarwal A, Gupta S, Mishra A, Singh N, Mishra S . Normotensive pheochromocytoma: institutional experience. World J Surg. 2005; 29(9):1185-8. DOI: 10.1007/s00268-005-7839-4. View

Proye C, Vix M, Goropoulos A, Kerlo P, Lecomte-Houcke M . High incidence of malignant pheochromocytoma in a surgical unit. 26 cases out of 100 patients operated from 1971 to 1991. J Endocrinol Invest. 1992; 15(9):651-63. DOI: 10.1007/BF03345810. View

10.

REMINE W, Chong G, Van Heerden J, Sheps S, HARRISON Jr E . Current management of pheochromocytoma. Ann Surg. 1974; 179(5):740-8. PMC: 1356065. DOI: 10.1097/00000658-197405000-00029. View

11.

Strong V, Kennedy T, Al-Ahmadie H, Tang L, Coleman J, Fong Y . Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis. Surgery. 2008; 143(6):759-68. DOI: 10.1016/j.surg.2008.02.007. View

12.

Miskulin J, Shulkin B, Doherty G, Sisson J, Burney R, Gauger P . Is preoperative iodine 123 meta-iodobenzylguanidine scintigraphy routinely necessary before initial adrenalectomy for pheochromocytoma?. Surgery. 2003; 134(6):918-22. DOI: 10.1016/s0039-6060(03)00416-1. View

13.

Kim H, Kim G, Sung G . Laparoscopic adrenalectomy for pheochromocytoma: comparison with conventional open adrenalectomy. J Endourol. 2004; 18(3):251-5. DOI: 10.1089/089277904773582859. View

14.

Davies M, McGlade D, Banting S . A comparison of open and laparoscopic approaches to adrenalectomy in patients with phaeochromocytoma. Anaesth Intensive Care. 2005; 32(2):224-9. DOI: 10.1177/0310057X0403200210. View

15.

Nativ O, Grant C, Sheps S, OFallon J, Farrow G, Van Heerden J . Prognostic profile for patients with pheochromocytoma derived from clinical and pathological factors and DNA ploidy pattern. J Surg Oncol. 1992; 50(4):258-62. DOI: 10.1002/jso.2930500413. View

16.

Linnoila R, KEISER H, Steinberg S, Lack E . Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features. Hum Pathol. 1990; 21(11):1168-80. DOI: 10.1016/0046-8177(90)90155-x. View

17.

ORiordain D, Young Jr W, Grant C, Carney J, Van Heerden J . Clinical spectrum and outcome of functional extraadrenal paraganglioma. World J Surg. 1996; 20(7):916-21; discussion 922. DOI: 10.1007/s002689900139. View